Hims Stock: One Big Mistake, One Bigger Bet. Is It Worth Owning?

Hims and Hers had a rough 2025 and early 2026. A partnership with one of the world's biggest weight loss drug makers fell apart. The stock crashed more than 30 percent in a single day. Then came a lawsuit. And a well-funded competitor is now ahead of them in the single most important health category of the decade. That chapter needs an explanation. And more importantly, it raises the question of whether the underlying business is still worth owning.